Research Article
Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis
Table 1
Clinical characteristics and body composition, in patients with rheumatoid arthritis.
| | Variables | |
| | Age (years) | | | RA disease duration (years) | | | Clinical characteristics | | | HAQ-DI score (units) | | | Active disease (), (%) | 68 (63) | | DXA measurement of body composition | | | Overweight or obesity, (%) | 76 (70.4) | | Lean mass (%) | | | , (%) | 105 (97.2) | | Treatment | | | Biologic-DMARDs, (%) | 13 (12) | | Synthetic-DMARDs, (%) | 105 (97.2) | | Methotrexate, (%) | 57 (52.8) | | Sulfasalazine, (%) | 40 (37) | | Leflunomide, (%) | 37 (34.3) | | Azathioprine, (%) | 15 (13.9) | | Chloroquine, (%) | 13 (12) | | Corticosteroid users, (%) | 88 (81.5) | | Laboratory variables | | | C-reactive protein (mg/L) | | | Erythrocyte sedimentation rate (mm/h) | | | Rheumatoid factor (IU/mL), | | | Positivity for rheumatoid factor (≥12 IU/mL), (%) | 57 (2.8) | | Serum TNF-α levels (ng/mL), | | | Serum IL-6 (pg/mL), | | | Serum anti-CCP levels (RU/mL), | | | Serum leptin levels (pg/ mL), | | | Serum NPY levels (pg/mL), | |
|
|
RA: rheumatoid arthritis; HAQ-DI: Health Assessment Questionnaire-Disability Index; DMARDs: disease-modifying antirheumatic drugs; TNF-α: tumor necrosis factor-alpha; IL-6: interleukin 6; NPY: neuropeptide Y.
|
